About wpadmin

This author has not yet filled in any details.
So far wpadmin has created 15 blog entries.

Lipum in EMBL Alumni Report 2017

The European Molecular Biology Laboratory (EMBL) was founded more than 40 years ago to be a centre of excellence for Europe’s most talented young scientists in the life sciences. In the Alumni Impact Report 2017 companies co-founded by EMBL alumni are listed, among those Lipum AB and Prof Lennart Lundberg. Read the report here.

2018-01-15T13:06:22+00:00

Horizon 2020 – Seal of Excellence

Seal of Excellence Certificate by European Commission In response to Lipums application ”Novel Target for Treatment of Chronic Inflammatory Diseases” for SME Instrument 2 funding by EU’s Horizon 2020 an international panel of independent experts scored it as a high-quality project proposal in a highly competitive evaluation process. The ”Seal of Excellence” certificate is issued for [...]

2017-11-30T11:05:09+00:00

November, meet us in Berlin and New York

Learn more about our novel target for treatment of chronic inflammatory diseases. We will attend: BIO-Europe in Berlin, Nov 6-8 Nordic-American conference in New York, Nov 13-14 RESI meeting in New York, Nov 15 We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected [...]

2017-11-09T21:19:50+00:00

BIO-Europe in Berlin Nov 6-8, meet Lipum there.

Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases. Lipum has collected original research data [...]

2017-11-02T10:58:13+00:00

Meet Lipum at NLSDays in Malmö, Sept 12-14

Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at Nordic Life Science Days 2017 in Malmö. A novel target molecule We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and [...]

2017-11-02T11:00:40+00:00

Future medicine for treatment of chronic inflammation

Rheumatism is an autoimmune disease that causes chronic inflammation and pain. The inflammation can break down cartilage, adjacent bones, tendons and arteries. Also eyes and other organs can be affected. About one percent of the population suffer of the disease. It is more common among women than men. Drug market for the disease is estimated to [...]

2017-06-28T16:30:09+00:00

A novel target and biological drug against chronic inflammatory diseases

Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at the NLSDays 2017. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development of a therapeutic antibody [...]

2017-11-02T11:05:50+00:00

Lipum patent granted in Canada

Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred to the company. The patent "New method for treatment of inflammatory diseases.", previously granted on most major markets, has now also been approved in Canada. [...]

2017-11-02T11:06:28+00:00

Lipum presenting at Anglonordic, London, May 31

We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance of our novel target molecule, the bile-salt stimulated lipase (BSSL). The development of a humanised antibody is in progress and Lipum is actively seeking partners [...]

2017-11-02T11:01:22+00:00